Effect of Rivaroxaban on Coagulation Parameters- an ex Vivo Study
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00986635|
Recruitment Status : Completed
First Posted : September 30, 2009
Last Update Posted : April 8, 2011
|Condition or disease|
|Differences in Laboratory Coagulation Parameters|
To validate the effects of Rivaroxaban on coagulation parameters plasma samples of patients after hip or knee replacement surgery treated with Rivaroxaban 10 mg/d are investigated.
Plasma samples are obtained by blood collection before, after 2 hours and after 12 hours after Rivaroxaban dosing in steady state (on 3rd - 5th day).
Several techniques, including clot-based tests, chromogenic assays and ELISA´s are used for coagulation assays in our coagulation laboratory Frankfurt/Main. The influence of Rivaroxaban on different coagulation assays should be investigated in our coagulation laboratory.
|Study Type :||Observational|
|Estimated Enrollment :||100 participants|
|Study Start Date :||September 2009|
|Actual Primary Completion Date :||June 2010|
|Actual Study Completion Date :||April 2011|
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00986635
|University Hospital Frankfurt|
|Frankfurt am Main, Germany, 60590|
|Principal Investigator:||Helen Mani, PhD||Johann Wolfgang Goethe University Hospital Frankfurt/Main Germany|